AIDS.GOV | SERVICE LOCATOR | SEARCH

BLOG.AIDS.GOV

MENU

Search Results for: "National Institute of Allergy and Infectious Diseases"

Appreciating Dr. Jack Whitescarver’s Many Contributions to HIV/AIDS Research

photo whitescarver

At the end of this month, we bid a fond farewell to a colleague who has played a key role in leading Federal research efforts in response to HIV/AIDS since the earliest days of the epidemic. As NIH previously announced, on July 1, 2015, Dr. Jack Whitescarver is retiring and stepping down as NIH’s Associate…

A Conversation with Dr. Anthony Fauci: Results from the START Trial and Implications for the Global Treatment of HIV

Anthony Fauci

Last week, NIH’s National Institute of Allergy and Infectious Diseases (NIAID) released the exciting results of the Strategic Timing of Antiretroviral Treatment (START) study, a randomized, controlled clinical trial to more clearly define the optimal time and benefits for people with HIV to begin antiretroviral therapy (ART). Given the implications of the study, AIDS.gov sat…

International Study Demonstrates Benefits of Early HIV Treatment

Dr. Anthony Fauci

The question of when to initiate antiretroviral therapy (ART) during the course of HIV infection has been debated for years, yet a conclusive answer has remained elusive. For HIV-infected individuals the primary question was whether to start ART early, risking possible cumulative drug toxicities, potential viral resistance, and difficulties with long-term adherence, or to defer…

Starting antiretroviral treatment early improves outcomes for HIV-infected individuals

nih logo

For Immediate Release: Wednesday, May 27, 2015 NIH-funded trial results likely will impact global treatment guidelines A major international randomized clinical trial has found that HIV-infected individuals have a considerably lower risk of developing AIDS or other serious illnesses if they start taking antiretroviral drugs sooner, when their CD4+ T-cell count—a key measure of immune…

BULLETIN: HIV Vaccine Awareness Day 2015

nih logo

May 18, 2015 Vaccination has historically been the best method for protecting against and ultimately defeating mankind’s most devastating infectious diseases. Although the path to developing a safe and effective HIV vaccine has so far been difficult, achieving this goal remains key to realizing a durable end to the global HIV/AIDS pandemic. HIV vaccine development…

HOPE Act to facilitate organ recovery from HIV-positive donors

HRSA logo

In a notice published in the Federal Register on May 8, 2015, the U.S. Department of Health and Human Services announced it will amend the OPTN Final Rule (42 CFR Part 121) to allow the recovery of transplantable organs from HIV-positive donors. This is a milestone in support of the federal HIV Organ Policy Equity…

NIH launches largest clinical trial focused on HIV-related cardiovascular disease

nhlbi logo

Researchers have begun enrolling participants in a multicenter international clinical trial to test whether statin administration can reduce the risk for major adverse cardiovascular events, such as heart attacks, strokes, and heart disease, in people with HIV infection. The trial is supported by the National Institutes of Health’s National Heart, Lung, and Blood Institute (NHLBI)…

Whitescarver steps down as director of NIH’s Office of AIDS Research

nih logo

Jack Whitescarver, Ph.D., who has led the Office of AIDS Research (OAR) at the National Institutes of Health since 2000, announced that he will step down from his post, effective July 1, 2015.  He also serves as NIH Associate Director for AIDS Research. The NIH will appoint an acting director for the office while it…